此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

MagnetOs 腻子与自体移植物在接受后外侧腰椎融合术患者中的上市后研究 (PROOF)

2026年11月3日 更新者:Kuros Biosurgery AG

一项前瞻性、随机、单中心研究,以评估 MagnetOs 腻子与自体移植物在接受两级仪器化后外侧腰椎/胸腰椎融合 (PLF) 的患者中的安全性和性能

This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.

In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.

研究概览

详细说明

In this study, following a screening period of a maximum of 30 days, 60 patients will undergo up to two-level instrumented posterolateral fusion (PLF) procedure. Prior to surgery, each patient will be randomized to receive MagnetOs Easypack Putty standalone on the assigned side of the spine and Demineralized Bone Matrix or Fibers mixed with local autograft bone on the other at the diseased levels. They will be followed up at discharge, Week 2, Month 3, Month 6, and Month 12. An interim analysis will be performed once 30 patients have completed their Month 6 visit and have measurements for the endpoints available to measure effectiveness. The primary endpoint will be analyzed at Month 12.

In this study, MagnetOs Easypack Putty will be applied according to the latest Instructions for Use approved in the United States. Specifically, MagnetOs Easypack Putty will be used standalone in patients up to two-level degenerative disc disease with segmental mechanical spinal instability requiring treatment with an instrumented posterolateral spine fusion procedure. The fusion procedure (PLF) will be left to the surgeon's discretion.

Radiographs will be obtained at Screening, Discharge, Month 3, Month 6 and Month 12. CT scans will only be obtained at Month 6 and Month 12.

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Irvine、California、美国、92697
        • The Regents of the University of California- Irvine Campus
    • Michigan
      • Grand Rapids、Michigan、美国、49503
        • Corewell Health
    • Missouri
      • St Louis、Missouri、美国、63130
        • The Washington University
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • Rothman Orthopaedic Institute
    • Tennessee
      • Nashville、Tennessee、美国、37209
        • Tennessee Orthopaedic Alliance
    • Washington
      • Seattle、Washington、美国、98104
        • University of Washington

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patient is able to read/be read, understand, and provide written informed consent and has signed the Institutional Review Board (IRB) approved informed consent.
  • Male or female patient ≥ 18 years old.
  • Patients with segmental mechanical spinal instability requiring arthrodesis surgery.

Instability can be either caused by degenerative disc disease or by traumatic injury to the spinal column. Patient requiring a maximum of two-level instrumented posterolateral lumbar/thoraco-lumbar fusion (T11 - S1) will be enrolled. Mechanical instability is defined by the presence of one or more of the following:

  1. instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),

  2. decreased disc height by > 2 mm, but dependent upon the spinal level

  3. Grade II or more listhesis

  4. TLICS equal or greater than 5

  5. Unstable burst fracture

    • Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment (if the patient undergoes elective surgery). Patients who have spinal instability (as defined above in inclusion criteria number three), caused by acute trauma requiring urgent surgical treatment are excluded from this criterion.

Exclusion Criteria:

  • Requires > two-level fusion or expected to need secondary intervention within one year following surgery.
  • Had prior PLF fusion or attempted PLF fusion at the involved levels.
  • Had previous decompression at the involved levels.
  • Women who are or intend to become pregnant within the next 12 months.
  • To treat conditions in which general bone grafting is not advisable.
  • In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilization is not possible).
  • In case of significant vascular impairment proximal to the graft site.
  • In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta, history of or active Pott's disease, stage >4 renal disease or Paget's Disease) that affect bone or wound healing.
  • In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
  • When intraoperative soft tissue coverage is not planned or possible.
  • Receiving treatment with medication interfering with calcium metabolism.
  • Has degenerative disc disease (DDD) related to a benign or malignant tumor.
  • Has history or presence of active malignancy.
  • Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.
  • Is involved in active litigation relating to his/her spinal condition.
  • Has participated in an investigational study within 30 days prior to surgery for study devices.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:MagnetOs Easypack Putty

Interventions

  • Procedure: Instrumented posterolateral spine fusion
  • Device; MagnetOs Easypack Putty

MagnetOs Easypack Putty used standalone in instrumented posterolateral fusion, 5cc-15c per spine level at the randomized assigned side.

有源比较器:Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed with local autograft bone

Interventions

  • Procedure: Instrumented posterolateral spine fusion
  • Device: Demineralized Bone Matrix or Fibers mixed with local autograft bone

Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed in a 1:1 vol% with local autologous bone graft used in instrumented posterolateral fusion, 5cc-15cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Radiographic Fusion by CT Scan
大体时间:Month 12

The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes.

Month 12

次要结果测量

结果测量
措施说明
大体时间
Radiographic Fusion by Plain Radiographs
大体时间:Month 6, Month 12

The rate of posterolateral lumbar/thoracolumbar fusion assessed by plain radiographs.

Month 6, Month 12
Radiographic Fusion by CT Scan
大体时间:Month 6

The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 6. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes.

Month 6
Functional Outcome by Oswestry Disability Index Questionnaire
大体时间:Screening, Week 2, Month 3, 6, and 12

Functional outcome by the Oswestry Disability Index questionnaire. Patient-completed questionnaire which gives a subjective percentage score of level of function (disability) in activities of daily living in those rehabilitating from low back pain. The lower the percentage the higher the patient's functionality. 0-20% minimal disability, 80-100% significant disability or bedridden.

Screening, Week 2, Month 3, 6, and 12
Back and Leg Pain by Visual Analog Pain Scale Questionnaire
大体时间:Screening, Week 2, Month 3, 6, and 12

Change in back and leg pain using Visual Analog Pain Scale (0-100). Patient-completed questionnaire scoring pain by using 100 mm line. Zero being no pain, 100 is worst pain imaginable.

Screening, Week 2, Month 3, 6, and 12
Neurologic Status by Physical Exam
大体时间:Screening, Week 2, Month 3, 6, and 12

Change in neurologic status by examination to document stable, improved, or deficits in condition. Stable or improved findings for lower extremities, specifically reflexes, muscle strength, sensory, and straight leg raise.

Screening, Week 2, Month 3, 6, and 12
Success Rate
大体时间:Week 2, Month 3, 6, and 12

Number of patients with secondary surgical interventions (SSI's) such as revisions, re-operations, removals, supplemental fixations, or any other procedure that adjusts or removes part of the original implant configuration with or without replacement of the components within 12 months of surgery.

Week 2, Month 3, 6, and 12

其他结果措施

结果测量
措施说明
大体时间
Safety Endpoint - number of patients with Adverse Events
大体时间:12 Months

The number of patients with Adverse Events from Screening up to Month 12 after surgery.

12 Months
Safety Endpoint - number of patients with Serious Adverse Events
大体时间:12 Months

The number of patients with Serious Adverse Events from Screening up to Month 12 after surgery

12 Months
Safety Endpoint - number of patients with Adverse Device Effects
大体时间:12 Months

The number of patients with Adverse Device Effects from Screening up to Month 12 after surgery.

12 Months
Safety Endpoint - number of patients with Device Related Complications
大体时间:12 Months

The number of patients with any complications considered to device related with 12 months after surgery.

12 Months
Health Economic - Duration of Surgery
大体时间:12 Months

Duration of surgery in minutes.

12 Months
Health Economic - Duration of Hospitalization
大体时间:12 Months

Duration of hospital stay in days.

12 Months
Health Economic - Return to Work
大体时间:12 Months

Time to return to work in days.

12 Months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Cesar Silva, MD、Kuros BioSciences B.V.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年12月6日

初级完成 (估计的)

2027年12月2日

研究完成 (估计的)

2027年12月30日

研究注册日期

首次提交

2020年12月18日

首先提交符合 QC 标准的

2020年12月18日

首次发布 (实际的)

2020年12月22日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅